Price (90d)
$26.79Signal Score (90d)
147Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.58B | $7.77B | $1.36 |
| 2024 | $63.63B | $8.02B | $1.42 |
| 2023 | $59.55B | $2.13B | $0.38 |
| 2022 | $100.33B | $31.36B | $5.59 |
| 2021 | $81.29B | $22.15B | $3.95 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.79 per share
Typical surprise +33.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.77 vs $0.68beat
- Tue, May 5$0.75 vs $0.72beat
- Tue, Feb 3$0.66 vs $0.57beat
- Tue, Nov 4$0.87 vs $0.63beat
- Tue, Aug 5$0.78 vs $0.58beat
- Tue, Apr 29$0.92 vs $0.67beat
Estimates and results for PFE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PFE's reported EPS growth of -23.4% a year over 4 years. Historical EPS growth of -23% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.61
- Implied price
- $10.92
- Return from $26.79
- -16.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.43 — -79.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -32.0% | -28.9% | -26.3% | -24.0% | -21.9% |
| -20.0% | -27.5% | -24.2% | -21.3% | -18.9% | -16.7% |
| -15.0% | -22.9% | -19.4% | -16.4% | -13.8% | -11.5% |
| -10.0% | -18.4% | -14.7% | -11.5% | -8.7% | -6.3% |
| -5.0% | -13.9% | -9.9% | -6.6% | -3.7% | -1.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (10)
- Newsbarrons.com·1d ago·Neutral
Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase Three Pfizer insiders executed transactions directly on the heels of the drugmaker's second-quarter earnings report.
View source ↗ - Newsfastcompany.com·1d ago·Negative
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug was taken off the market in 2021.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
…yme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
View source ↗ - PodcastAll In·2d ago·Neutral
…ths. And their efficacy is in the 60%. And we know for a fact that a lot of Chinese leaders were not taking the Chinese vaccine, but they were end up taking quietly, Pfizer, Moderna, etc. And they couldn't export the vaccine. Nobody in the third world, that's a huge opportunity for America. We squandered it. I'm a political side of the economic side of the cultural side. Winning, quote unquote, the global side. Second, gene makes a decision that will never happen again. Massively invests in the …
View source ↗ - Newszacks.com·3d ago·Neutral
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth? PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Pfizer's Pipeline Could Change Everything Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attractive valuation supporting upside potential. PFE's Q2 2026 results showed 1% operational revenue growth and a 12% EPS beat, driven by solid non-COVID sales and a robust growth portfolio. Cost Realignment Program expansions are set to deliver $7.2B in net savings by 2026 and another $2.5B through 2029, enhancing future earnings.
View source ↗ - Newszacks.com·5d ago·Neutral
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.
View source ↗ - News (RSS)seekingalpha·6d ago·Neutral
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
View source ↗ - News (RSS)seekingalpha·6d ago·Neutral
Insider trades: Microsoft, Meta, Pfizer among notable names
View source ↗ - News (RSS)cnbc·10d ago·Negative
Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
View source ↗